Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
-
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
-
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
-
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
-
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
-
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
-
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
-
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference